2+ day, 19+ hour ago   (80+ words) Sept 11 (Reuters) - ​The ‌U.S. Food and ‌Drug ​Administration ⁠on ⁠Friday approved Scholar ​Rock's ⁠therapy ⁠to ​treat ​a rare genetic ‌condition ⁠that causes muscle ⁠weakness. (Reporting ‌by ⁠Sneha ​S ‌K in ​Bengaluru; ⁠Editing by Tasim ​Zahid)... US FDA approves Scholar…...

4+ day, 5+ hour ago   (278+ words) Sept 10 (Reuters) – Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental ​epilepsy drug after rodent findings, sending its shares ‌down more than 13% in premarket trading. Here are…...

5+ day, 5+ hour ago   (872+ words) Sept 9 (Reuters) – Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona. A drug being developed by AstraZeneca significantly reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, researchers reported on…...

5+ day, 23+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

6+ day, 3+ hour ago   (85+ words) Sept 8 (Reuters) - AstraZeneca said ​on ‌Tuesday its cancer ‌drug ​Imfinzi ⁠combined with ⁠Amgen's targeted immunotherapy Imdelltra ​significantly ⁠improved ⁠overall survival ​in ​first-line extensive-stage small ‌cell lung ⁠cancer in a ⁠late-stage ‌... AstraZeneca’s cancer drug combo hits main survival goal in late-stage…...

6+ day, 5+ hour ago   (249+ words) Sept 8 (Reuters) – Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main ​goal of a late-stage trial. Shares of the ‌company were up over 25% in premarket trading. • Hereditary angioedema causes…...

6+ day, 5+ hour ago   (105+ words) Sept 8 (Reuters) – Bristol Myers Squibb said on Tuesday its ​experimental cell ‌therapy for a type of blood cancer had met the main ‌goal ​of a ⁠mid-stage trial. The company ⁠was testing the therapy, called arlocabtagene autoleucel, or arlo-cel, in ​patients…...

6+ day, 10+ hour ago   (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s ​impact on myotonic dystrophy, a form ‌of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...

1+ week, 5+ hour ago   (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its ​experimental cardiovascular drug ziltivekimab, further ‌denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...

1+ week, 2+ day ago   (160+ words) Sept 4 (Reuters) – Ionis Pharmaceuticals and partner Novartis’ experimental drug to lower high levels of a ​cholesterol-carrying particle in heart patients ‌failed in a late-stage trial, the companies said on Friday. Shares of Ionis fell 6% in aftermarket trading. The drug, pelacarsen,…...